



## UPDATE FROM THE CEO

Last July I reached out to you with a special newsletter explaining a remarkable acquisition we have negotiated for your company. I referred to it in a light-hearted manner as, “The Oncolytic Express,” as the analogy of a direct line with a determined arrival point appealed to me.

Well it’s now November and after a carefully charted journey we are about to pull into the station, our EGM, on the 18th of this month. We need you to board and go on the next leg of our journey with us. Your vote for our acquisition of the CF33 oncolytic virotherapy technology is important and needed if we are to proceed.

Firstly, a brief refresher if I may. The CF33 oncolytic virus is the creation of Professor Yuman Fong, the chair of the department of surgery at the acclaimed City of Hope Hospital in Los Angeles.

The hospital, founded in 1913 is internationally recognised for


its work in in the fields of liver, pancreas, gall bladder and bile duct cancers and is designated a “comprehensive,” cancer centre, the highest recognition awarded by the American National Cancer Institute. Professor Fong leads the team that directs genetically modified viruses to destroy cancer cells.

It’s appropriate to mention that Professor Fong and his colleague, Dr. Yanghee Woo, recently received a United States Department of Defence grant for \$815,000 AUD in research into CF33 and its possible role in the fight against gastric cancer.

We’ve told you about CF33 in detail in our last newsletter but to briefly sum up it is a chimeric vaccinia virus with significant historical reference as it was an active ingredient in the eradication of smallpox.

It is in two forms;

1. armed with an immune checkpoint inhibitor inserted in the virus we call “CHECKvacc”
2. the other is an unarmed form we call “Vaxinia.” Both will enter phase one trials in 2020.



Both are genetically modified viruses that attack, replicate and eventually kill cancer cells whilst leaving healthy cells unharmed.

We have negotiated an exclusive and worldwide license for this technology.


All of this of course conditional on your support. That’s why I’m writing to you today as I thought an update for your consideration would be appropriate before you cast your vote.

Our website has full detail on what’s been occurring since last July and I respectfully refer you to it for full scientific appraisal.



### CHECKvacc Proposed Triple Negative Breast Cancer Study

Phase 1 – Dose Seeking/Signal Finding





# THE INVENTOR OF CF33 IS PROF YUMAN FONG.

The Oncolytic Express would not be spinning its wheels without the deft touch of its chief engineer.

The term renaissance man is not one you hear much of these days but without the slightest hesitation I venture the opinion that the man at the controls of our express fits that description and more. As a scientist he is acclaimed as an innovator, inventor and hands on surgeon in his particular disciplines. He has developed innovative surgical techniques and instruments, written over 700 scholarly articles and authored 14 textbooks. He serves as the chair of the recombinant DNA advisory committee of The National Institute of Health of The United States. He has been inducted into the American Institute of Medical and Biologic Engineering distinction only given to 2% of engineers. He also has kindly agreed to chair our newly formed oncolytic virotherapy scientific advisory board.

That's professor Fong the scientist. Professor Fong the man is altogether something else and his personal activities and achievements resonate with our Aussie way of life.

He's a former rugby player and a marksman of note (a talent he passed on to two of his daughters who are on the USA Olympic shooting team). He has published comic books to help children understand the complexities of fighting cancer. He's an expert in the field of

artificial intelligence. He plays viola.

With a life as full as his I once asked him, "what's your main focus on life?" He did not wax eloquent or give me a worldly dissertation, he simply said, "taking care of my patients." He recently received the Master Clinician Award from the American Society of Surgery of the Alimentary Tract (only one annually awarded).

That's the kind of man who will be leading the Imugene team

with a focus on the exciting and remarkable field of oncolytic virotherapy...CF33 has arrived.

With your help of course. We need your vote. Our executive chairman, Paul Hopper and I welcome you to attend the EGM or if you can't make it I'm always available at the office and would welcome hearing from you.

**Warmest Regards,  
Leslie**

